FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent…

Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus

ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today…

Our Africa by Merck Foundation on GHOne TV, Ghana with Their 7th Episode to Address Coronavirus Health Awareness

Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany released the Seventh Episode of their TV program – “Our Africa by Merck Foundation” at 2 pm on Sunday, 26th June 2022 on GHOne, Ghana, repeated at 1:30…

Merck Foundation Announced 67 Winners of Merck Foundation Mask up with Care Media Awards 2021 to Raise Awareness About Coronavirus

Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany in partnership with African First Ladies announced the winners of Merck Foundation “Mask up with Care” Media Recognition Awards 2021 with the aim to raise awareness about Coronavirus in…

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause…

NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at the Benzinga…

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its…

Plasmacluster Technology Demonstrates Effectiveness in Reducing Airborne Novel Coronavirus (Including Variant) Contained in Adherent Saliva (SARS-CoV-2), a World First

Business Wire IndiaIn world’s first, Sharp Corporation, Japan has developed a device equipped with Plasmacluster Ion technology that shows more than 90% reduction on airborne Novel Corona Virus (SARS-CoV-2) in 30 seconds, while when exposed to adhering Novel Corona Virus…

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus

HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ — Insilico Medicine and Westlake Pharma announced a strategic partnership to jointly develop innovative small-molecule drugs for Novel Coronavirus (COVID-19) today. The cooperation will be based on the anti-COVID-19 drug R&D project by Westlake Pharma,…

Sputnik V vaccine effective against new variants of coronavirus, the Gamaleya Center study published in Vaccines leading international journal, shows

– The Gamaleya Center is actively studying emerging variants of SARS-CoV-2 to access efficacy of Sputnik V against new strains as the virus is still evolving in various parts of the world. – Study methodology is described in the research paper…